Measles, a disease once considered largely defeated in the United States, has made a dramatic comeback during the past two years. As of August 2026, the United States was experiencing its highest number of measles cases in decades.

In 2024, the Centers for Disease Control and Prevention (CDC) recorded 285 measles cases nationwide. That number jumped to 2,289 cases in 2025, an increase of more than 700 percent. The situation has continued to worsen in 2026. As of July 30, the CDC had recorded 2,371 confirmed cases, meaning that only seven months into the year the country had already surpassed the entire 2025 total. Ninety-four percent of the 2026 cases were associated with outbreaks.

The resurgence of measles cases in the past two years illustrates how even a relatively small decline in vaccination rates can create pockets of vulnerable people large enough for one of the world’s most contagious viruses to spread. Measles was declared eliminated in the United States in 2000 because vaccination rates were high enough to prevent imported infections from producing sustained outbreaks. Today that protective barrier has weakened due to significantly fewer people getting vaccinated…

In the 1800s, John D. Rockefeller started refining oil into the world's most valuable fuel. Now, another innovator is creating its own “Rockefeller Moment” with one of the world’s most abundant energy resources: coal.

This is more important than ever right now, because a perfect storm of operational breakthroughs and policy shifts has the potential to directly impact this company’s valuation. 

What’s creating this "Rockefeller Moment” for coal? 

Using their patented FASForm technology, Frontieras can transform coal into high-value commodities like hydrogen, diesel, jet fuel, and fertilizer, without burning it.

They’re targeting a combined $2.1 trillion in markets where demand for these commodities is virtually unlimited. 

Reaching just 2% of the global coal market could mean a trillion-dollar valuation for Frontieras. 

That’s why the "smart money" is already moving. Frontieras has secured a $150M investment commitment from GEM and raised over $30 million from private investors.

But here’s why 2026 is shaping up to be such a historic year for this company:

Become a Frontieras shareholder by August 6 to lock in the $9.01 share price.

The recommended measles, mumps and rubella, or MMR, vaccine is highly effective: one dose provides approximately 93 percent protection against measles, and two doses provide about 97 percent protection. Maintaining vaccination coverage of approximately 95 percent is considered particularly important because measles spreads so easily. Yet MMR coverage among American kindergartners declined from 95.2 percent in the 2019-2020 school year to 92.5 percent in 2024-2025. That left roughly 286,000 kindergartners without complete MMR protection during the 2024-2025 school year.

The national percentage can also conceal much larger vulnerabilities within particular communities. Some schools, counties and religious or cultural communities have vaccination rates far below the national average. Once an infected traveler introduces measles into one of these areas, the virus can spread rapidly. In 2026, 93 percent of reported cases involved people who were unvaccinated or whose vaccination status was unknown, underscoring the connection between gaps in immunization and outbreaks.

Measles initially produces fever, cough, runny nose, irritated eyes, and a characteristic rash, but complications can include pneumonia and encephalitis, or brain swelling. The CDC estimates that roughly one in five unvaccinated Americans who contracts measles requires hospitalization, while approximately one in 1,000 infected children develops encephalitis. Between one and three of every 1,000 infected children may die. Three confirmed measles deaths occurred in the United States during 2025.

Before the first measles vaccine was licensed in the U.S. in 1963, the virus infected 3 to 4 million Americans annually, causing roughly 48,000 hospitalizations and 400 to 500 deaths each year. At the turn of the twentieth century, measles killed on average over six thousand people each year in the U.S.

The decline in vaccination rates is likely due to a drop in trust among the American public and vaccines in general. That drop in trust itself is a legacy of the covid-19 pandemic, which continues to generate controversy six years afterwards. The politicization of vaccines by proponents and opponents of the covid-19 vaccine appears to have left a lasting decrease in Americans trust in vaccines and the overall health care system.

*Disclaimer: This is a paid advertisement for Frontieras’s Regulation A offering. Please read the offering circular at https://invest.frontieras.com/ 

Reservation of the ticker symbol is not a guarantee that we will be listed on the NASDAQ.  Listing on the NASDAQ is subject to approvals. 

Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.